A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India - Trial NCT06370715
Access comprehensive clinical trial information for NCT06370715 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eli Lilly and Company and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 112 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 4
Apr 18, 2024
Jul 01, 2025
Primary Outcome
Percentage of Participants with at least 1 Episode of Hypoglycemia
Summary
The purpose of this study is to assess the safety of insulin lispro-aabc in adult
 participants with Type 2 diabetes mellitus in India.
 
 The study will last about 33 weeks for each participant, including screening (1 week),
 Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370715
Non-Device Trial